Research programme: botulinum toxin-based therapeutics - Allergan/ MeditoxAlternative Names: botulinum toxin; botulinum toxin B - Medytox
Latest Information Update: 05 Aug 2015
At a glance
- Originator Medy-Tox
- Class Bacterial proteins; Bacterial toxins
- Mechanism of Action Neuromuscular blocking agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Spasm